Feed

Diabetes mellitus is a prevalent chronic condition with major impact on quality of life. Traditional treatment relied on insulin injections and self-monitoring, but advances in diabetes technology, such as continuous glucose monitoring (CGM), insulin pumps, and Hybrid Closed-Loop (HCL) systems, now provide new opportunities for optimizing glycemic control. HbA1c remains the established marker for long-term outcomes, though complementary use of Time in Range (TIR) offers more detailed insight into daily glucose variability. Clinical evidence shows that technologies such as CGM, HCL, and connected devices can reduce HbA1c, increase TIR, and lower the risk of severe hypoglycemia, while also improving quality of life and psychosocial outcomes. However, implementation must be tailored to individual patients, considering motivation, skills, and context. Future developments, including fully closed-loop systems, further highlight the need for clinicians to remain informed about rapidly evolving technologies and to critically assess their added value in daily practice.